The Time is Now: Prospective Surveillance and the New NAPBC Standards
Wednesday, October 7th, 6pm ET
Featured Faculty: Nicole L. Stout DPT, CLT-LANA, FAPTA
Overview
One care delivery model has the potential to elevate your clinical practice towards improving surveillance workflows that align to several of the new NAPBC standards. In 2027, Standard 5.8 will require Lymphedema Assessment protocols, Standard 5.15 will require a Return to Wellness protocol, and Standard 5.16 will require a Surveillance protocol for long-term and late effects. Implementing a prospective surveillance care delivery model, using baseline and interval surveillance timepoints throughout the care continuum is an opportunity to create one clinical pathway that helps your breast cancer center align to all three of these standards. This webinar will review the evidence for prospective surveillance, highlight key time points and clinical measures that are most relevant to these standards, and will share implementation strategies that can help your practice optimize workflows that optimize surveillance over time.
Learning Objectives
- Identify the prospective surveillance model evidence-based clinical pathway elements and timeline.
- Understand how the model enables a surveillance pathway that can support clinical alignment to the new NAPBC standards.
- Discuss measurement tools, staffing models, and workflow elements based on successful implementation cases.
Featured Faculty
Nicole L. Stout DPT, CLT-LANA, FAPTA
Dr. Stout is the Senior Director of Survivorship and Wellness at the American Cancer Society where she leads a portfolio of national strategic initiatives in lifestyle medicine and caregiver support across pediatric, adolescent, and adult oncology. She has an international reputation in the field of cancer rehabilitation and survivorship care with over 25 years of experience in clinical research focusing on supportive care delivery and early rehabilitation in cancer. Her research has been foundational to developing the prospective surveillance model for morbidity management in cancer care. She has given over 400 scientific lectures nationally and internationally, authored and co-authored over 150 peer-review and invited publications, several book chapters, and is the co-author of the book 100 Questions and Answers about Lymphedema. Dr. Stout has led national and international strategic initiatives advancing survivorship research, guideline development, and policy solutions in cancer care. She is also an adjunct research faculty member of the West Virginia University Cancer Institute, where she supports clinical implementation research.